The National COVID Cancer Antibody Survey: a hyper-accelerated study proof of principle for cancer research

The COVID-19 pandemic has led to a range of novel and adaptive research designs. In this perspective, we use our experience coordinating the National COVID Cancer Antibody Survey to demonstrate how a balance between speed and integrity can be achieved within a hyper-accelerated study design. Using t...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of cancer Vol. 128; no. 11; pp. 1977 - 1980
Main Authors Fittall, Matthew, Liu, Justin, Platt, James, Ionescu, Maria, Sheehan, Remarez, Johal, Sukhmunni, Mew, Rosie, Clark, James, Watts, Izzy, Tripathy, Arvind, Little, Martin, Patel, Grisma, Panneerselvam, Hari, Appanna, Nathan, Burke, Emma, McKenzie, Hayley, Tilby, Michael, Khan, Sam, Lee, Lennard Y. W.
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 15.06.2023
Nature Publishing Group
Subjects
692/308/174
692/308/2779/109/2425
692/53/2422
Antibodies
Biomedical and Life Sciences
Biomedicine
Cancer
Cancer Research
Charities
Clinical trials
Consent
Coronaviruses
COVID-19
COVID-19 diagnostic tests
COVID-19 vaccines
Datasets
Delivery of Health Care
Drug Resistance
Epidemiology
Hospitalization
Hospitals
Humans
Immunization
Immunoglobulins
Medical research
Molecular Medicine
Neoplasms
Oncology
Pandemics
Participation
Patients
Perspective
Primary care
Research design
Surveys
Online AccessGet full text

Cover

More Information
Summary:The COVID-19 pandemic has led to a range of novel and adaptive research designs. In this perspective, we use our experience coordinating the National COVID Cancer Antibody Survey to demonstrate how a balance between speed and integrity can be achieved within a hyper-accelerated study design. Using the COVID-19 pandemic as an example, we show this approach is necessary in the face of uncertain and evolving situations wherein reliable information is needed in a timely fashion to guide policy. We identify streamlined participant involvement, healthcare systems integration, data architecture and real-world real-time analytics as key areas that differentiate this design from traditional cancer trials, and enable rapid results. Caution needs to be taken to avoid the exclusion of patient subgroups without digital access or literacy. We summarise the merits and defining features of hyper-accelerated cancer studies.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0007-0920
1532-1827
DOI:10.1038/s41416-023-02251-9